Publications in collaboration with researchers from Hospital del Mar (11)

2015

  1. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish registry

    Leukemia, Vol. 29, Núm. 9, pp. 1875-1881

  2. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: A population-based study

    The Lancet Haematology, Vol. 2, Núm. 6, pp. e260-e266

2014

  1. Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations

    Leukemia

  2. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis

    Leukemia Research, Vol. 38, Núm. 3, pp. 304-309

2013

  1. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome

    Journal of Clinical Oncology, Vol. 31, Núm. 7, pp. 916-922

2012

  1. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome

    Cancer, Vol. 118, Núm. 1, pp. 127-133

  2. Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes

    British Journal of Haematology, Vol. 159, Núm. 3, pp. 311-321

  3. Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival

    Annals of Hematology, Vol. 91, Núm. 12, pp. 1887-1895

2011

  1. Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome

    Leukemia Research, Vol. 35, Núm. 6, pp. 834-836

  2. Cytogenetic risk stratification in chronic myelomonocytic leukemia

    Haematologica, Vol. 96, Núm. 3, pp. 375-383

  3. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome

    Cancer, Vol. 117, Núm. 24, pp. 5529-5537